Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
253 studies found for:    Neurotoxicity
Show Display Options
Rank Status Study
1 Completed
Has Results
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Conditions: Colorectal Cancer;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
2 Unknown  Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
3 Recruiting Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Monosialoganglioside(GM1);   Drug: normal saline
4 Unknown  Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neurotoxicity
Interventions: Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
5 Terminated A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity
Condition: Neurotoxicity Syndromes
Intervention: Drug: Dextromethorphan
6 Recruiting Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel 80 mg/m2;   Drug: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1 and 15
7 Active, not recruiting Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
Condition: Colorectal Cancer
Interventions: Drug: monosialotetrahexosylganglioside Sodium;   Other: placebo
8 Active, not recruiting Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: monosialotetrahexosylganglioside Sodium;   Other: placebo
9 Unknown  Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
Condition: Cancer
Interventions: Drug: oxaliplatin;   Procedure: management of therapy complications
10 Unknown  Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Conditions: Breast Neoplasms;   Breast Diseases;   Metastases, Neoplasm
Interventions: Drug: BNP7787;   Drug: Placebo
11 Completed
Has Results
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
Conditions: Kidney Cancer;   Leukemia;   Lymphoma;   Neurotoxicity;   Peripheral Neuropathy;   Sarcoma
Interventions: Drug: glutamic acid;   Other: placebo
12 Completed Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Interventions: Drug: Paclitaxel;   Drug: EPO
13 Recruiting Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway
Condition: Neurotoxicity
Intervention: Drug: Vitamin D3
14 Recruiting Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Conditions: Male Breast Cancer;   Neurotoxicity;   Peripheral Neuropathy;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Other: laboratory biomarker analysis;   Other: questionnaire administration
15 Completed Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity
Conditions: Neurotoxic Disorders;   Cancer
Intervention: Drug: Mangafodipir
16 Recruiting Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer
Conditions: Colorectal Cancer;   Chemotherapy-induced Neutropenia
Interventions: Drug: GM1;   Drug: placebo;   Drug: mFOLFOX6 or XELOX
17 Completed XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Conditions: Metastases;   Colorectal Neoplasms;   Colorectal Carcinoma
Intervention: Drug: SR57746A
18 Completed Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Conditions: Metastases;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: xaliproden (SR57746A);   Drug: Placebo;   Drug: oxaliplatin
19 Completed Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity
Condition: Colorectal Neoplasms
Interventions: Drug: Glutamine;   Drug: Calcium and Magnesium
20 Terminated Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors
Condition: Primary Central Nervous System Lymphoma (PCNSL)
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years